
The sell-off of the UK’s future vaccine manufacturing site has been branded “ridiculously short-sighted” after a US pharmaceutical firm announced it had bought the factory.
In a statement published on its website on Wednesday, Catalent said it had acquired the site in Oxfordshire but did not state how much it had paid.